Amelioration of fatigue in chronic dialysis patients with dialysis solution employing electrolyzed water containing molecular hydrogen (H2) and its association with autonomic function balance
Yoshihiro Tsujimoto, Daisuke Kuratsune, Shigeru Kabayama, Mariko Miyazaki, Yasuyoshi Watanabe, Yoshiki Nishizawa, Masaaki Nakayama · Renal Replacement Therapy · 2021
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 2 patients with subjective symptoms on HD and HD-free days, during the 8-week observation period of E-HD, VAS scores were significantly decreased on HD days in Group A, while Group B showed no significant changes in VAS on HD days, but significant decreases on HD-free days. These findings add human evidence that helps define the outcomes that did and did not change with molecular hydrogen in this study.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in 2 patients with subjective symptoms on HD and HD-free days. During the 8-week observation period of E-HD, VAS scores were significantly decreased on HD days in Group A, while Group B showed no significant changes in VAS on HD days, but significant decreases on HD-free days.
What the Researchers Studied
The researchers studied 2 patients with subjective symptoms on HD and HD-free days. The study used a human clinical study.
What Effects Did Molecular Hydrogen Have?
During the 8-week observation period of E-HD, VAS scores were significantly decreased on HD days in Group A, while Group B showed no significant changes in VAS on HD days, but significant decreases on HD-free days. The authors concluded that e-HD may ameliorate fatigue in patients with subjective symptoms on HD and HD-free days.
Why These Findings Matter
This publication adds useful evidence about where molecular hydrogen did and did not change the measured outcomes, helping define the larger therapeutic evidence base.
How Strong Is This Evidence?
This is human clinical evidence from a human clinical study. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 2 patients with subjective symptoms on HD and HD-free days. The reported sample size was 95. The study used a human clinical study.
Limitations and Safety
No separate limitations or safety findings were identified in the current-study source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base. The original scholarly source is available at https://link.springer.com/article/10.1186/s41100-021-00376-2/fulltext.html.